

# Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

## NCI-H1648

RRID:CVCL\_1482

Type: Cell Line

### Proper Citation

RRID:CVCL\_1482

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1482](https://web.expasy.org/cellosaurus/CVCL_1482)

**Proper Citation:** RRID:CVCL\_1482

**Description:** Cell line NCI-H1648 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Lung adenocarcinoma

**Defining Citation:** [PMID:1311061](#), [PMID:8806092](#), [PMID:9559342](#), [PMID:10987304](#), [PMID:11030152](#), [PMID:16187286](#), [PMID:18083107](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:35839778](#)

**Comments:** Population: African American., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** NCI-H1648

**Synonyms:** H1648, H-1648, NCIH1648

**Cross References:** CLO:CLO\_0008006, EFO:EFO\_0003119, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5882, BioSample:SAMN03473271, BioSample:SAMN10988142, cancercellines:CVCL\_1482, Cell\_Model\_Passport:SIDM00746, ChEMBL-Cells:ChEMBL3308315, ChEMBL-Targets:ChEMBL2366214, Cosmic:687799, Cosmic:877244, Cosmic:877428,

Cosmic:903597, Cosmic:931372, Cosmic:980979, Cosmic:1028941, Cosmic:1032451, Cosmic:1146882, Cosmic:1152511, Cosmic:1154594, Cosmic:1219083, Cosmic:1239886, Cosmic:1891893, Cosmic:1995529, Cosmic:2125235, Cosmic:2628355, Cosmic:2629444, Cosmic-CLP:687799, DepMap:ACH-000766, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:687799, GEO:GSM62326, GEO:GSM108817, GEO:GSM108818, GEO:GSM253366, GEO:GSM434268, GEO:GSM794323, GEO:GSM817085, GEO:GSM887372, GEO:GSM888450, GEO:GSM1670180, IARC\_TP53:499, IARC\_TP53:21403, IGRhCellID:H1648GEO, LiGeA:CCLE\_277, LINCS\_HMS:50032, LINCS\_LDP:LCL-1632, PharmacDB:NCIH1648\_1027\_2019, PRIDE:PXD030304, Progenetix:CVCL\_1482, PubChem\_Cell\_line:CVCL\_1482, Wikidata:Q54907837

**ID:** CVCL\_1482

**Record Creation Time:** 20220427T220838+0000

**Record Last Update:** 20260829T234741+0000

---

## Ratings and Alerts

No rating or validation information has been found for NCI-H1648.

No alerts have been found for NCI-H1648.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 8 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Jeong J, et al. (2025) NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. *Nature*.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. *Molecular cell*, 85(7), 1311.

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. *Cancer research*, 85(18), 3518.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Aboukassim T, et al. (2023) A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants. *Cell reports*, 42(9), 113104.

Orlando E, et al. (2022) An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cellular and molecular life sciences : CMLS, 80(1), 6.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell chemical biology, 27(1), 105.

Ge P, et al. (2019) miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. BMC cancer, 19(1), 1203.